Table 1a:
Indication | Results |
---|---|
Major Depressive Disorder | |
Symptoms, Treatment Response, Remission |
CBT vs. control (usual care, clinical management, or wait list) Cuijpers et al20
Linde et al21(primary care patients)
Churchill et al22
|
ADM + CBT vs. CBT only (acute treatment) Karyotaki et al35
|
|
ADM + CBT vs. ADM only (acute treatment) Karyotaki et al35
|
|
ADM + CBT vs. ADM only (maintenance treatment) Karyotaki et al35
|
|
SGA vs. CBT Amick et al36
|
|
SGA only vs. SGA + CBT Amick et al36
Acute CBT (without continuation CBT) vs. acute ADM (with continued ADM) Cuijpers et al37
|
|
Acute CBT (without continuation CBT) vs. acute ADM (discontinued at follow-up) Cuijpers et al37
|
|
Relapse/Recurrence |
CBT vs control (usual care, clinical management, or wait list) Biescheuvel-Leliefeld et al29
Clarke et al30
Guidi et al31
|
Adverse Events | Not reported |
Quality of Life | Not reported |
Generalized Anxiety Disorder | |
Symptoms, Treatment Response, Remission |
Compared with control (usual care, clinical management, or wait list) Cuijpers et al20
Cuijpers et al53
Hunot et al11
|
Relapse/Recurrence | Not reported |
Adverse Events | Not reported |
Quality of Life | Compared with control (usual care, clinical management, or wait list) |
Hunot et al11 | |
Improvement in quality-of-life score: SMD = 0.44 (95% CI: 0.06–0.82) |
Abbreviations: ADM, antidepressant medication; BDI, Beck Depression Inventory; CBT, cognitive behavioural therapy; CI, confidence interval; GAD, generalized anxiety disorder; HDRS, Hamilton Depression Rating Scale; MDD, major depressive disorder; OR, odds ratio; SGA, second-generation antidepressant; SMD, standardized mean difference; WMD, weighted mean difference.
Defined by Churchill et al as no longer having a clinically meaningful level of depression (as measured by a BDI score < 10 or an HDRS score < 6).22